Litigation Details for ENDO PAR INNOVATION COMPANY, LLC v. DEVA HOLDING A.S. (D.N.J. 2023)

ENDO PAR INNOVATION COMPANY, LLC v. DEVA HOLDING A.S. (D.N.J. 2023)

Docket	1:23-cv-21684	Date Filed	2023-10-31
Court	District Court, D. New Jersey	Date Terminated	2023-12-21
Cause	35:271 Patent Infringement	Assigned To	Christine P. O'Hearn
Jury Demand	None	Referred To	Sharon A. King
Patents	9,119,876; 9,295,657
Link to Docket	External link to docket

Details for ENDO PAR INNOVATION COMPANY, LLC v. DEVA HOLDING A.S. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-10-31				External link to document

Litigation summary and analysis for: ENDO PAR INNOVATION COMPANY, LLC v. DEVA HOLDING A.S. (D.N.J. 2023)

Last updated: July 24, 2026

ENDO PAR INNOVATION COMPANY, LLC v. DEVA HOLDING A.S. (1:23-cv-21684): Litigation Summary, Patent Claims, and Generic-Entry Risk

Executive summary: The federal case ENDO Par Innovation Company, LLC v. Deva Holding A.S. is filed as No. 1:23-cv-21684 (D.N.J.) and is framed as a patent dispute tied to Deva’s effort to market a generic version that ENDO asserts infringes listed patents. The action’s practical risk is that, depending on which patents are asserted and whether the case targets a specific ANDA product and drug strength, Deva’s launch timeline could be constrained by (i) court-ordered injunctive relief, (ii) settlement terms covering “at-risk” entry, or (iii) patent-expiration and exclusivity schedules that govern final FDA approval timing.

However, no docket facts, asserted patents, claim construction history, or orders are provided in the prompt, so a complete litigation summary (including the asserted patent numbers, causes of action, procedural posture, and outcomes) cannot be produced.